Clinical trial · Interventional
Bone Regeneration Using PRF After Cyst Enucleation
Clinical Efficacy of Platelet-Rich Fibrin in Osseous Regeneration After Cystic Enucleation
NCT07424716CI-TRIAL-00103771PRF-BonerecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized controlled clinical trial aims to evaluate the clinical efficacy of autologous platelet-rich fibrin (PRF) in promoting osseous regeneration following cystic enucleation in the jaws. The study will assess bone healing outcomes and compare PRF application with conventional management methods.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Jaw Cysts | — | UNRESOLVED | — |
| Odontogenic Cyst | — | UNRESOLVED | — |
| Osseous Defect After Cyst Enucleation | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autologous Platelet-Rich Fibrin (PRF) | Biological | — | UNRESOLVED |
| Conventional Surgical Management | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PRF Group
- description
- Participants undergoing cystic enucleation in the jaws will receive autologous Platelet-Rich Fibrin (PRF) placed into the osseous defect immediately after surgical enucleation.
- interventionNames
- Biological: Autologous Platelet-Rich Fibrin (PRF)
- type
- ACTIVE_COMPARATOR
- label
- Control Group
- description
- Participants undergoing cystic enucleation of jaw cysts will receive conventional surgical management without the application of platelet-rich fibrin (PRF). The osseous defect will be left to heal naturally following standard enucleation and wound closure procedures.
- interventionNames
- Procedure: Conventional Surgical Management
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with odontogenic cysts requiring surgical enucleation. * Presence of a postoperative osseous defect in the jaws after cyst enucleation. * Age ≥ 18 years. * Systemically healthy patients (ASA I or II). * Patients willing to participate and sign informed consent. Exclusion Criteria: * Patients with systemic diseases affecting bone healing (e.g., uncontrolled diabetes, osteoporosis). * Patients receiving bisphosphonates or long-term corticosteroid therapy. * Smokers (\>10 cigarettes/day). * Pregnant or lactating women. * Patients with acute infection at the surgical site. * Patients unwilling to participate or unable to attend follow-up visits.
References
Publications (0)
Data not yet available
No reference posted for this study.